Plasma endothelin-1 levels after stem cell transplantation.

Area of Science:

• Nephrology
• Hepatology
• Hematology
• Transplantation Immunology

Background:

• Stem cell transplantation (SCT) is associated with severe renal and hepatic complications, contributing to non-relapse mortality.
• Endothelins, potent vasoconstrictors, are implicated in renal and hepatic diseases, including CsA-associated hypertension and hepatorenal syndrome.
• The role of endothelins in SCT-related organ dysfunction requires further investigation.

Purpose of the Study:

• To investigate the relevance of endothelin-1 (ET-1) in the pathogenesis of kidney and liver dysfunction following SCT.
• To determine plasma ET-1 levels in patients undergoing SCT at various time points before and after the procedure.

Main Methods:

• Plasma samples were collected from 65 patients (38 autologous, 27 allogeneic) 7 days before SCT and 7, 14, and 28 days after SCT.
• Plasma ET-1 levels were measured using validated assays.
• Statistical analyses were performed to compare ET-1 levels between different time points, SCT types, and patient groups with or without renal/hepatic dysfunction.

Main Results:

• A statistically significant steady increase in plasma ET-1 levels was observed from pre-SCT baseline to day +28 post-SCT (P = 0.020).
• No significant differences in ET-1 levels were found between autologous and allogeneic SCT recipients.
• No significant associations were identified between plasma ET-1 levels and the development of renal dysfunction (P = 0.187) or hepatic dysfunction (P = 0.075).

Conclusions:

• Plasma ET-1 levels increase following SCT, suggesting a potential systemic response.
• Despite the observed increase in ET-1, this study found no correlation with the development of SCT-related kidney or liver dysfunction.
• Further research is needed to elucidate the precise role of endothelins in the pathophysiology of SCT complications.